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Abstract
MicroRNAs are often associated with the pathogenesis of many cancers including Head and Neck 
Squamous Cell Carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to play a 
critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study we 
investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the 
stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA 
binding to CD44 promotes Nanog-Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, 
nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is 
controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin 
immunoprecipitation (ChIP) assays demonstrate that stimulation of miR-21 expression by HA/
CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a 
tumor suppressor protein (PDCD4), and an upregulation of inhibitors of the apoptosis family of 
proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- 
and/or Stat-3-specific small interfering RNAs (siRNAs) effectively blocks HA-mediated Nanog-
Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. 
Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein 
(IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in 
tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 
inhibitor in order to silence miR-21 expression and block its target functions. Our results 
demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression, but also decreases 
IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these 
findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 plays a pivotal role 
in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in 
HNSCC cells. This novel Nanog/Stat-3 signaling pathway-specific mechanism involved in 
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miR-21 production is significant for the formation of future intervention strategies in the treatment 
of HA/CD44-activated HNSCC.
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is a malignancy that involves cancers of 
the lip, oral cavity, pharynx, hypopharynx, larynx, nose, nasal, sinuses, neck, ears and 
salivary glands (Parkin, et al., 2005). Advanced HNSCC is an aggressive disease associated 
with major morbidity and mortality. The three-year survival rate for patients with advanced-
stage HNSCC treated with standard therapy is only 30 to 50%. Resistance to standard 
therapy continues to be a limiting factor in the treatment of HNSCC. Nearly 40 to 60% of 
HNSCC patients subsequently develop chemoresistance, locoregional recurrences or distant 
metastases (Jemal, et al. 2008; Parkin, et al. 2005). Thus, clarification of key aspects of 
tumor cell functions underlying the clinical behavior of HNSCC is greatly needed.
Previous studies identified specific extracellular matrix (ECM) components in head and 
neck squamous cell carcinoma (HNSCC) that correlate with tumor cell behaviors (Wang and 
Bourguignon, 2011). Among such candidate molecules is hyaluronan (HA) which is a 
nonsulfated, unbranched glycosaminoglycan consisting of repeating disaccharide units, D-
glucuronic acid and N-acetyl-D-glucosamine (Toole and Hascall, 2002). HA interacts with 
CD44, a family of cell-surface glycoprotein receptors which are also expressed in a variety 
of human solid neoplasms, particularly those classified as HNSCC (Wang, et al., 2009). 
Both CD44 and HA are overexpressed/elevated at sites of tumor attachment (Toole and 
Hascall, 2002; Toole, et al., 2002). HA binding to CD44 not only affects cell adhesion to 
extracellular matrix (ECM) components, but also is involved in the stimulation of a variety 
of tumor cell-specific functions leading to cytoskeleton function and HNSCC progression 
(Turley, et al., 2002; Bourguignon, 2008). However, the oncogenic mechanism(s) occurring 
during HA-activated and CD44-specific HNSCC progression remain(s) to be determined.
The stem cell marker, Nanog is an important transcription factor involved in the self-
renewal and maintenance of pluripotency in the inner cell mass (ICM) of mammalian 
embryo and of embryonic stem (ES) cells (Mitsui, et al., 2003). Nanog signaling is regulated 
by interactions among various pluripotent stem cell regulators (e.g., Rex1, Sox2 and Oct3/4) 
which together control the expression of a set of target genes required for ES cell 
pluripotency (Mitsui, et al., 2003). These findings confirm the essential role of Nanog in 
regulating a variety of cellular functions. Recently, several tumor cell types have been 
shown to express Nanog (Ezeh, et al., 2005; Bourguignon, et al., 2008). HA binding to 
epithelial tumor cells has been shown to promote Nanog protein association with CD44, 
followed by Nanog activation and the expression of pluripotent stem cell regulators (e.g., 
Rex1 and Sox2) (Bourguignon, et al., 2008). These findings strongly suggest that HA/CD44 
signaling and Nanog function are tightly linked.
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The “signal transducer and activator of transcription protein 3” (Stat-3) was initially 
identified as APRF (Acute Phase Response Factor), an inducible DNA binding protein that 
binds to the IL-6-responsive element within the promoters of hepatic acute phase genes 
(Darnell, 1997, Heinrich, et al., 2003). Accumulating evidence indicates that Stat-3 also 
plays an important role in regulating cell growth, differentiation, and survival (Huang, 
2007). Nanog and Stat-3 also appear to be both structurally linked and functionally coupled 
in HA/CD44 signaling during epithelial tumor cell activation (Bourguignon, et al., 2008). 
The question of whether Nanog and Stat-3 are interacting with each other in HNSCC cells 
will be addressed in this study.
A number of studies indicate that more than 50% of microRNA [(miRNA), small RNA 
molecules with ~20–25 nucleotides] are located in cancer-related genomic regions or fragile 
sites, suggesting that miRNA may be closely associated with the pathogenesis of a variety of 
cancers including HNSCC (Chang, et al., 2008; Volinia, et al., 2006). Analysis of an array 
profile of miRNA expression in HNSCC tissues reveals that miR-21 is abundantly produced 
in these tumors compared to normal tissues (Volinia, et al., 2006). The functional 
significance of miR-21 has been elucidated in several recent studies following the discovery 
of its specific targets (Asangani, et al., 2008), making miR-21 one of the most-studied 
miRNAs due to its involvement in cancer progression. Importantly, miR-21 plays a role in 
the inhibition of tumor suppressor proteins such as Program Cell Death 4 (PDCD4), via a 
conserved site within the 3′-UTR (3′-untranslated region) of the mRNA (Asangani, et al., 
2008; Bourguignon, et al., 2009a). Downregulation of PDCD4 expression by miR-21 leads 
to tumor cell growth, survival, chemoresistance, invasion and metastasis (Bourguignon, et 
al., 2009a). Thus, miR-21 is currently considered to be an oncogenic miRNA. Whether HA/
CD44-mediated Nanog (or Stat-3) signaling is involved in regulating oncogenic miRNA 
(e.g., miR-21) expression/function and tumor-specific behaviors in HNSCC cells has not 
been determined, and represents the primary focus of this study.
In this study we discovered a new matrix HA/CD44-mediated Nanog/Stat-3 signaling 
mechanism that regulates miR-21 production and chemoresistance in HNSCC cells. 
Specifically, our results indicate that HA/CD44 activates Nanog-Stat-3 signaling which, in 
turn, stimulates miR-21 expression and function. These events lead to the reduction of the 
tumor suppressor protein, PDCD4, upregulation of survival proteins and cisplatin 
chemoresistance in HNSCC cells. Inhibition of either Nanog/Stat-3 signaling or silencing 
miR-21 expression/function not only results in PDCD4 upregulation, but also causes a 
reduction of survival protein expression and an enhancement of chemosensitivity to 
cisplatin. Thus, our findings strongly support the contention that Nanog, Stat-3, and miR-21 
form a functional signaling axis that regulates tumor cell survival and cisplatin 
chemoresistance in HNSCC cells.
RESULTS
HA-mediated CD44 interaction with Nanog and Stat-3 in HSC-3 Cells
Previous studies showed that both Nanog and Stat-3 are functionally coupled during 
oncogenesis (Bourguignon, et al., 2008). Among the signaling aberrations present in 
HNSCC, Stat-3 activation appears to be one of the critical pathways in HNSCC 
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development and progression (Song and Grandis, 2000). Cellular transformation by Stat-3 
generally requires specific phosphorylation of the tyrosine 705(pY705) residue (Wen, et al., 
1995). In this study we first examined whether Nanog and Stat-3 are expressed in clinical 
HNSCC tissue specimens. Primary HNSCC tumors were immunostained with antibodies for 
Nanog, total Stat-3 and tyrosine phosphorylated Stat-3. Fig. 1A shows representative 
examples of the immunohistochemical staining of HNSCC primary tumors for both Nanog 
and Stat-3 (Fig. 1A-a & b). We have also observed co-localization of Nanog with tyrosine 
phosphorylated Stat-3 and total Stat-3 (Fig. 1A-c-e and Fig. 1A-f-h) in HNSCC patient 
samples. These findings clearly demonstrated that a close association between Nanog and 
Stat-3 (including tyrosine phosphorylated Stat-3) occurs in head and neck cancer patient 
samples.
HA/CD44-mediated oncogenic signaling has been implicated in both the initiation and 
development of several solid tumors including head and neck cancer (Bourguignon, et al., 
2008, 2009a; Huang, 2007; Toole and Hascall, 2002; Wang, et al., 2009; Wang and 
Bourguignon, 2011). However, the cellular and molecular mechanisms by which HA/CD44 
signaling occurs in HNSCC cells are still poorly understood. In this study we have focused 
on the question of whether there is a physical linkage between CD44 and tyrosine 
phosphorylated Stat-3[pY705] in HNSCC cells [e.g., HSC-3 cell line (Fig. 1)]. To this end 
we performed a HA-mediated Stat-3 tyrosine phosphorylation time course (e.g., 0, 5, 15 and 
60min) using anti-CD44-mediated immunoprecipitation followed by anti-Stat-3[pY705] 
immunoblot or anti-CD44 immunoblot, respectively. Our results indicate that the association 
of phosphorylated Stat-3 with CD44 occurs as early as 5min following HA addition to 
HNSCC cells (Fig. 1B).
Next, we investigated whether there is an interaction between Nanog and total Stat-3 in the 
CD44-associated signaling complex in HNSCC cells [e.g., HSC-3 cells (Fig. 1C)]. 
Specifically, we performed anti-CD44-mediated immunoprecipitation followed by anti-
Nanog immunoblot or anti-total Stat-3/anti-Stat-3[pY705] immunoblot or anti-CD44 
immunoblot (Fig. 1C), respectively, using cells treated with HA or without HA. Our results 
indicate that a 5min HA treatment causes the recruitment of Nanog and total Stat-3 (together 
with tyrosine phosphorylated Stat-3) (Fig. 1C-a,b, c) into the CD44 complex (Fig. 1C-d). In 
contrast, a low level of Nanog or Stat-3 (or tyrosine phosphorylated Stat-3) is present in the 
anti-CD44-immunoprecipitated materials (reblotted with anti-CD44) in cells not treated with 
HA (Fig. 1C-a, b, c, d) or in cells pretreated with anti-CD44 antibody followed by a 5min 
HA treatment (Fig. 1C-a, b, c, d). These findings clearly establish that CD44, Nanog and 
Stat-3 (in particular, tyrosine phosphorylated Stat-3) are closely associated with each other, 
and that there is a significant increase in the recruitment of Nanog, Stat-3 (also 
phosphorylated Stat-3) into the CD44-associated complex following a 5min HA treatment of 
HSC-3 cells.
Elucidate Nanog/Stat-3 nuclear translocation, complex formation and transcription 
activation in HNSCC cells following HA-CD44 binding
Several studies have suggested the importance of HA/CD44-mediated nuclear translocation 
of transcription factors in regulating target gene expression and tumor cell activation 
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(Bourguignon, et al. 2008Bourguignon, et al. 2009a and 2010). In this study using 
immunofluorescence staining and confocal microscopy, we observed that both Nanog and 
Stat-3 can be translocated from the cytosol to the nucleus after 15 min HA treatment (Fig. 
2A). In contrast, the majority of Nanog and Stat-3 is distributed in the cytosol and only a 
low level of Nanog and Stat-3 is present in the nucleus of HSC-3 cells, either pretreated with 
anti-CD44 antibody plus HA (Fig. 2A) or without any HA treatment (Fig. 2A). These 
observations indicate that HA-CD44 interaction promotes Nanog and Stat-3 nuclear 
translocation in HNSCC cells.
In order to examine whether Nanog interacts with Stat-3 (in particular tyrosine 
phosphorylated Stat-3) directly in the nucleus of HSC-3 cells, we analyzed the anti-Nanog-
mediated immunoprecipitates from nuclear extracts by immunoblotting with anti-total 
Stat-3/anti-p-Stat-3[pY705], or anti-Nanog antibody, respectively. Our results demonstrate 
that very little amount of Nanog is complexed with either total Stat-3 or tyrosine 
phosphorylated Stat-3 in the nuclear fractions of HSC-3 cells without any HA treatment 
(Fig. 2B-a, b, c). Importantly, we observed that a 15 min HA treatment of HSC-3 cells 
stimulates a measurable increase in the amount of Nanog and total Stat-3/tyrosine 
phosphorylated Stat-3 complexes (Fig. 2B-a, b, c) in the nuclear fractions of HSC-3 cells. 
When these tumor cells were pretreated with anti-CD44 antibody followed by a 15min HA 
treatment, the complex formation between Nanog and total Stat-3/tyrosine phosphorylated 
Stat-3 in the nuclear fraction is greatly reduced in HSC-3 cells (Fig. 2B-a, b, c). These 
findings suggest that Nanog is capable of forming with Stat-3 (in particular, tyrosine 
phosphorylated Stat-3) (in the nucleus) in a HA-dependent and CD44-specific manner in 
HSC-3 cells.
Role of Stat-3 in regulating miR-21 expression in HA/CD44 and Nanog-activated HSC-3 
cells
(1) In vivo binding of Stat-3 to the upstream/enhancer region of the miR-21 
promoter in HSC-3 cells—A previous study indicated that the gene encoding oncogenic 
miR-21 is regulated by an upstream/enhancer promoter containing Stat-3 binding sites 
(Löffler D, 2007). To examine whether Nanog-associated Stat-3 directly interacts with the 
upstream/enhancer region of miR-21 promoter, anti-Stat-3 antibody-, anti-phospho-
Stat-3[pY705] and anti-Nanog antibody-specific chromatin immunoprecipitation (ChIP) 
assays were performed in HSC-3 cells. As shown in Fig. 3, the PCR from both anti-Stat-3, 
anti-phospho-Stat-3[pY705] and anti-Nanog-mediated precipitations from HA-treated HSC-3 
cells resulted in a specific amplification product using primer pair specific for the miR-21 
promoter/enhancer region containing the Stat-3 binding sites (Fig. 3A-a, b, c, lane 2). In 
contrast, reduced amount of Nanog is associated with the Stat-3 or phospho-Stat-3 binding 
of miR-21 upstream/enhancer promoter region in cells pretreated with anti-CD44 antibody 
followed by HA addition (Fig. 3A-a,b,c, lane 3), or without HA treatment (Fig. 3a,b,c, lane 
1). These findings suggest that the recruitment of Stat-3 (also phospho-Stat-3) and Nanog 
into the upstream/enhancer region of miR-21 promoter site is HA-specific and CD44-
dependent.
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To confirm the direct involvement of Stat-3 and Nanog in miR-21 gene upregulation, both 
Stat-3 and Nanog were first downregulated by Stat-3 siRNA or Nanog siRNA, respectively 
followed by the miR-21 promoter-specific ChIP assay as described above. Our results 
indicate that transfection of HNSCC cells with Nanog siRNAs (Fig. 3A-a,b,c, lane 6) or 
Stat-3 siRNA (Fig. 3A-a,b,c, lane 7), but not scrambled sequenced siRNA (Fig. 3A-a,b,c, 
lane 4 vs. lane 5) effectively blocks HA-mediated Nanog/Stat-3 binding to the miR-21 
upstream/enhancer promoter region in HNSCC cells. Identical amplification products were 
detected in the positive controls from total input chromatin (Fig. 3A-e, lane 1–7). Moreover, 
no amplification was seen in samples that were processed in IgG isotype control-mediated 
precipitation (Fig. 3A-d, lane 1–7). We observed similar results by quantitative RT-PCR 
(data not shown). Thus, these results verify that Nanog-associated Stat-3 binds directly (or 
forms as part of the complex) to the promoter region of miR-21 in HSC-3 cells following 
HA-CD44 interaction.
In order to establish the specificity of the Stat-3/Nanog siRNAs used in this study, HSC-3 
cells were transfected with siRNA sequences targeting human Nanog or Stat-3 followed by 
immunoblotting with anti-Stat-3 antibody or anti-Nanog antibody, respectively. Our results 
clearly indicate that Stat-3 siRNA target sequences successfully suppress the expression of 
Stat-3 (but not Nanog) in HNSCC cells (Fig. 3B-a,b,c), whereas Nanog siRNA target 
sequences effectively block Nanog (but not Stat-3) expression in HNSCC cells (Fig. 3B-
a,b,c). In control samples, neither Stat-3 nor Nanog is downregulated in HSC-3 cells treated 
with transfection reagents containing scrambled siRNA (Fig. 3B-a,b,c). Therefore, we 
conclude that the downregulation of Stat-3 or Nanog expression by either Stat-3 siRNA or 
Nanog siRNA used in our study is specific.
(2) Production of miR-21 in HNSCC cells—The expression of mature-miR-21 has 
been shown to be involved in HNSCC progression (Chang, et al., 2008; Volinia, et al., 
2006). To determine whether miR-21 levels are increased following the binding of HA to 
CD44, we first prepared small RNAs followed by an RNase protection assay using the 
miRNA Detection Kit (Ambion). Our results indicate that the level of miR-21 is increased in 
HSC-3 cells treated with scrambled sequence siRNA plus HA (Fig. 4a-lane 2) compared 
with those cells without HA treatment (Fig. 4a-lane 1). HSC-3 cells treated with Nanog 
siRNA (Fig. 4a-lane 4) or Stat-3 siRNA (Fig. 4a-lane 5) show significantly less HA-induced 
miR-21 expression. These findings support the notion that both Nanog and Sta-3 are 
required for miR-21 production in HA-activated HNSCC cells. We also noted that the 
increase of miR-21 expression was specifically a result of the interaction between HA and 
CD44 since pretreatment of HSC-3 cells with anti-CD44 antibody plus HA addition 
significantly reduces miR-21 production (Fig. 4a-lane 3). Moreover, we have found that the 
expression of miR-21 can be induced in cells treated with a miRNA-negative control upon 
addition of HA (Fig. 4a-lane 7 vs. lane 6). In contrast, the treatment of HSC-3 cells with an 
anti-miR-21 inhibitor plus HA results in a decrease in miR-21 expression (Fig. 4a-lane 8). 
We believe that these changes in miR-21 expression under various treatment conditions was 
not due to the variations of RNA extracted from each sample since there were very similar 
levels of the miR-191 control in all samples (Fig. 4b-lane 1–8). Together, these findings 
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strongly suggest that HA/CD44-activated Nanog and Stat-3 signaling plays an important 
role in the production of miR-21 in HNSCC cells.
The impact of HA/CD44-mediated miR-21 (induced by Nanog and Stat-3 signaling) in 
PDCD4/IAP expression, anti-apoptosis and chemoresistance in HSC-3 cells
PDCD4 was identified as one of the tumor suppressor genes induced by miR-21 (Asangani, 
et al., 2008). Inhibitors of the apoptosis family of proteins (IAPs) [e.g., cIAP-1, cIAP-2 and 
X-linked IAPs (XIAP)] are frequently overexpressed by cancer cells. Importantly, 
upregulation of IAPs (c-IAP-1, c-IAP-2 and XIAP) is linked to chemoresistance by their 
binding to caspases and suppressing apoptosis (Hunter, 2007). Here, we demonstrate that 
basal levels of PDCD4 expression and IAPs were detected in cells treated with scrambled 
sequence siRNA without HA addition (Fig. 5a, lane 1; Fig. 5b-d, lane 1) or pretreated with 
anti-CD44 antibody followed by HA addition (Fig. 5a, lane 3; Fig. 5b-d, lane 3). In contrast, 
PDCD4 expression was significantly reduced and IAPs are greatly enhanced in cells treated 
with scrambled sequence siRNA in the presence of HA (Fig. 5a, lane 2; Fig. 5b-d, lane 2). 
Further analyses indicate that HSC-3 cells treated with Nanog siRNA or Stat-3 siRNA (in 
the presence of HA) displays an elevated level of PDCD4 expression (Fig. 5a, lane 4 and 
lane 5) and a decreased amount of XIAP expression (Fig. 5b-d, lane 4 and lane 5). These 
observations confirm that HA/CD44-mediated Nanog and Stat-3 signaling is closely linked 
to the expression of PDCD4 and/or IAPs in HSC-3 cells. We also noted that downregulation 
of miR-21 by treating HSC-3 cells with an anti-miR-21 inhibitor (but not a negative-control 
miRNA) promotes upregulation of PDCD4 expression (Fig. 5a, lane 8 vs. lane 6 and lane 7) 
and downregulation of IAPs (Fig. 5b-d, lane 8 vs. lane 6 and lane 7) in the presence of HA. 
These results indicate that the signaling network consisting of Nanog, Stat-3 and miR-21 is 
functionally coupled with the inhibition of the tumor suppressor protein (PDCD4) 
expression and the stimulation of survival protein (e.g., XIAP) production. These specific 
effects may facilitate the progression of HA/CD44-activated HNSCC cells.
Further analyses indicate that the addition of HA enhances cell growth/survival and reduces 
apoptosis in untreated control cells or anti-CD44 antibody treated cells (i.e., without 
chemotherapeutic drugs) and decreases the ability of cisplatin to induce tumor apoptosis and 
cell death (Table 1A). These observations strongly suggest that HA causes both a decrease 
in apoptosis and an increase in tumor cell growth and survival (Table 1A) leading to the 
enhancement of chemoresistance (Table 1A). Moreover, downregulation of Nanog, Stat-3 or 
miR-21 [by treating HSC-3 cells with Nanog siRNA or Stat-3 siRNA or transfected HSC-3 
cells with an anti-miR-21 inhibitor (but not scrambled sequence siRNA or with miRNA-
negative control)] effectively attenuates HA-mediated tumor cell growth/anti-apoptosis/
survival and enhances multi-drug sensitivity in HSC-3 cells (Table 1A). These findings 
suggest that the HA/CD44-mediated Nanog/Stat-3 signaling pathways and miR-21 function 
may represent new targets to cause tumor cells to undergo apoptosis/death and overcome 
chemotherapy resistance in head and neck cancer cells.
Apparently, both PDCD4 loss and IAP protein gain are responsible for HA-mediated 
cisplatin resistance in HNSCC cells (Fig. 5). Recently, a small molecule IAP protein 
inhibitor (bivalent SM-164) has been shown concurrently target cIAP-1/cIAP-2 for 
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degradation and antagonize XIAP leading to an enhancement of tumor cell apoptosis and 
tumor regression (Lu, et al. 2008). In this study, we have found that chemosensitivity 
increases with a newly developed IAP protein inhibitor, SM164 (Table 1B). These findings 
suggest that the use of a combination of IAP protein inhibitor (SM164) and cisplatin may 
improve the efficacy of chemotherapeutic drug treatments for head and neck cancer.
DISCUSSION
The primary tumor type in head and neck cancer is squamous cell carcinoma (HNSCC). 
These tumor cells display persistent cell growth leading to chemoresistance and recurrence 
(Parkin, et al., 2005). Hyaluronan (HA), the major glycosaminoglycan found in the 
extracellular matrix of mammalian tissues, is now considered to be a physiologically-
relevant ligand for CD44 (also known as a hyaluronan receptor) in many cell types including 
HNSCC cells (Wang and Bourguignon, 2011). Most of malignant solid tumors display high 
levels of both HA and CD44 (Toole and Hascall, 2002; Toole, et al., 2002; Wang and 
Bourguignon, 2009). HA-CD44 interaction has been shown to promote oncogenic signaling 
and tumor cell-specific properties (Turley, et al., 2002; Bourguignon, 2008). In this study we 
focused on determining which oncogenic pathways are directly involved in regulating HA 
and CD44-specific HNSCC cell behaviors such as chemotherapy resistance.
Nanog has been suggested as one of the major factors that render the reprogramming adult 
stems into germ-line-competent induced pluripotent stem (iPS) cells (Kashyap, et al., 2009). 
It is expressed not only in germ cell tumors, but also found to be expressed in many other 
tumors including HNSCC cells and tissues (Chiou, et al., 2008). In this study we also 
detected Nanog expression in HNSCC cells (e.g., HSC-3 cells) (Figs. 1 and 2). The fact that 
Nanog overexpression is closely associated with HNSCC cells and tissues suggests that its 
expression may be implicated in self-renewal and tumorigenesis via activating its 
downstream target genes. The question of how Nanog signaling pathway plays a role in 
regulating HNSCC cell activation has not been well-understood.
Overexpression miR-21 is detected in various HNSCC cell lines and patient specimens 
(Volinia, et al., 2006; Chang, et al., 2008). Accumulating evidence indicates that miR-21 is 
closely associated with both cancer development and chemotherapy resistance 
(Bourguignon, et al., 2009a). Nanog appears to be involved in the regulation of pri-miRNA 
expression during cancer development (Bourguignon, et al., 2009a). Our previous work 
showed that HA/CD44-activated PKCε promotes Nanog interaction with p68 and DROSHA 
leading to biosynthetic processing and production of miR-21 in breast tumor cells 
(Bourguignon, et al., 2009). These findings suggest that HA/CD44-mediated Nanog 
signaling is closely linked to miR-21 production and function during oncogenesis.
Abnormal Stat-3 signaling appears to play a critical role in oncogenesis (Huang, 2007). In 
particular, constitutive activation of Stat-3 such as tyrosine phosphorylated Stat-3 has been 
observed in human malignancies including HNSCC (Huang, 2007). Previous studies showed 
that the functional link between Nanog and Stat-3 exists in several different tumor cells 
(Bourguignon, et al., 2008). In this study we observed that HA-CD44 binding activates 
Nanog/Stat-3 (also tyrosine phosphorylated Stat-3) nuclear localization and complex 
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formation in HSC-3 cells (Figs. 1–3). Thus, identifying specific genes that are 
transcriptionally controlled by the Nanog-Stat-3 interaction in the nucleus may be very 
important for the understanding of the disease mechanism occurring during HNSCC 
progression. Activation of Stat-3 has also been shown to up-regulate the mRNA levels of 
many genes, including miR-21 (Löffler D, 2007).
Here, we have provided new evidence that HA/CD44 activates Nanog-Stat-3 (also p-Stat-3) 
complex formation and nuclear translocation in HNSCC cells (Figs. 1 and 2). Our results 
also indicate that miR-21 is controlled by an upstream promoter/enhancer containing Stat-3 
binding sites in HNSCC cells, while chromatin immunoprecipitation (ChIP) assays 
demonstrate that stimulation of miR-21 production by HA is Nanog/Stat-3 complex-
dependent in HNSCC cells (Fig. 3). Most importantly, an anti-miR-21 inhibitor can enhance 
PDCD4 expression (Fig. 5), and block HA/CD44-mediated tumor functions [e.g., survival 
protein expression (Fig. 5), tumor cell growth and survival/chemotherapy resistance (Table 
1)] in HNSCC cells. Thus, this newly-discovered HA/CD44-Nanog/Stat-3 signaling 
pathway and miR-21 production/function are highly innovative and should provide 
important new drug targets to cause tumor cell apoptosis and overcome chemotherapy 
resistance in head and neck cancer cells.
Cisplatin is the most common anti-head and neck chemotherapy used today. The ability of 
this drug to induce tumor cell death is often counteracted by the presence of anti-apoptotic 
regulators leading to chemoresistance (Nakamura, et al., 2005; Torre, et al., 2010; Wang and 
Bourguignon, 2011). Several lines of evidence point toward the IAP family (e.g., c-IAP-1, c-
IAP-2 and XIAP) playing a role in oncogenesis via their effective suppression of apoptosis 
(Hunter, 2007). The mode of action of IAPs in suppressing apoptosis appears to be through 
direct inhibition of caspases and pro-caspases (primarily caspase 3 and 7) (Hunter, 2007). 
IAPs also support chemoresistance by preventing tumor cell death induced by anticancer 
agents (Gyrd-Hansen and Meier, 2010). Although certain anti-apoptotic proteins (e.g., Bcl-
xL) have been shown to participate in anti-apoptosis and chemoresistance in HA/CD44-
activated breast tumor cells (Bourguignon, et al., 2009b), the involvement of IAPs in HA/
CD44-mediated HNSCC cell survival and chemoresistance has not been fully elucidated.
In this study we demonstrated that HA/CD44-activated Nanog/Stat-3 signaling and miR-21 
reduce PDCD4 expression (Fig. 5) resulting in oncogenesis [by enhancing the expression of 
inhibitors of anti-apoptosis proteins (IAPs) (Fig. 5)]. Furthermore, downregulation of HA/
CD44-activated Nanog/Stat-3 signaling (by Nanog siRNA/Stat-3 siRNA) and miR-21 
production (by anti-miR-21 inhibitor) not only induces PDCD4 upregulation (Fig. 5), but 
also inhibits the expression of survival proteins (e.g., c-IAP-1, c-IAP-2 and XIAP) (Fig. 5). 
Subsequently, these signaling perturbation events contribute to apoptosis and 
chemosensitivity (Table 1). Our preliminary data indicate that (i) PDCD4 downregulation 
can be detected as early as 30–60 min after HA binding to CD44, whereas IAP protein 
upregulation can be detected 5–6 hours after HA-CD44 interaction; and (ii) PDCD4 
overexpression blocks IAP protein expression. After 24h HA addition, a maximal level of 
PDCD4 loss and IAP overexpression can be reached in HNSCC cells. Therefore, this time 
point was used in Fig. 5. However, the cellular and molecular mechanisms involved in the 
regulation of these causal links between Nanog/Stat-3 signaling and miR-21 function 
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including PDCD4 dowregulation, IAP upregulation, anti-apoptosis and chemoresistance will 
need to be resolved by further experiments.
As summarized in Fig. 6, we propose that HA binding (Step 1) promotes CD44 association 
with Nanog and Stat-3 (also tyrosine phosphorylated Strat-3, p-Stat-3) (step 2). Nanog and 
Stat-3 (also p-Stat-3) then translocate from the cytosol to the nucleus and interacts with an 
upstream/enhancer region (containing Stat-3 binding sites) of the miR-21 promoter (step 4), 
resulting in miR-21 gene expression and mature miR-21 production (step 5). The resultant 
miR-21 then functions to downregulate the tumor suppressor protein (PDCD4) (step 6a) and 
promotes HNSCC cell activation (step 7a) leading to IAP (c-IAP-1, c-IAP-2 and XIAP) 
expression, HNSCC cell anti-apoptosis/survival and chemoresistance. In direct contrast, 
treatment of HNSCC cells with an anti-miR-21 inhibitor induces tumor suppressor protein 
(PDCD4) upregulation (step 6b). Subsequently, these changes result in the inhibition of IAP 
(c-IAP-1, c-IAP-2 and XIAP) expression (Fig. 7b), stimulation of apoptosis and 
enhancement of chemosensitivity in HNSCC cells. Taken together, these findings suggest 
that targeting HA/CD44-mediated Nanog-Stat-3 signaling pathways and miR-21 function 
may provide a new drug target to sensitize tumor cell apoptosis/death and overcome 
chemotherapy resistance in HNSCC cells.
MATERIALS AND METHODS
Cell Culture
The cell line, HSC-3 cells (Japan Cancer Research Resources Bank, Tokyo), was established 
in 1985 from a primary oral squamous cell carcinoma removed from the tongue of a 64-
year-old male patient. The HSC-3 cells were maintained in Dulbecco Modified Eagle 
medium supplemented with 10% fetal bovine serum. Cells were routinely serum starved 
(and therefore deprived of serum HA) before adding HA.
Antibodies and Reagents
Monoclonal rat anti-CD44 antibody (Clone: 020; Isotype: IgG2b; obtained from CMB-
TECH, Inc., San Francisco, CA.) recognizes a determinant of the HA-binding region 
common to CD44 and its principal variant isoforms. This rat anti-CD44 was routinely used 
for HA-related blocking experiments and immunoprecipitation. Immuno-reagents such as 
rabbit anti-Stat-3 antibody, goat anti-Nanog antibody, mouse anti-PDCD4 antibody, and 
goat anti-actin antibody were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA). Mouse anti-c-IAP-1 antibody, mouse anti-c-IAP-2 and mouse anti-XIAP antibody 
were from BD (Franklin Lakes, NJ). Rabbit anti-phospho-Stat-3 (pY[705], tyrosine 705 
residue) was from Cellular Signaling Technology (Beverly, MA). Cisplatin, was obtained 
from Sigma Chemicals (St. Louis, MO). Healon HA polymers (~500,000dalton polymers), 
purchased from Pharmacia & Upjohn Company (Kalamazoo, MI) was prepared by gel 
filtration chromatography using a Sephacryl S1000 column (GE Healthcare Biosciences).
Anti-miR-21 Inhibitor Preparation and Transfection
Anti-miR™ targeting miR-21 (anti-miR-21 inhibitor) (Ambion, catalog number, 17000) and 
its corresponding negative control (Ambion, catalog number, 17010) were transfected into 
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HSC-3 cells using Lipofectamine 2000 reagent (Invitrogen) for 24h. Cells were then treated 
with HA or without HA in various experiments as described below. The final concentrations 
of anti-miR-21 inhibitor and miRNA-negative control used in various experiments were 
30nmol/L.
Immunoprecipitation and Immunoblotting Techniques
Immunoprecipitation was conducted after homogenization of the cell lysate using rat anti-
CD44 antibody followed by goat anti-rat IgG-beads. Subsequently, the immunoprecipitated 
materials were immunoblotted with rabbit anti-Nanog antibody (2μg/ml) or rabbit anti-
Stat-3 antibody (2μg/ml) or rabbit anti-phospho-Stat-3 (pY[705]) (2μg/ml). The nuclear 
fraction [using the extraction kit from Active Motif (Carsbad, CA)] of HSC-3 cells 
(untreated or pretreated with anti-CD44 antibody) plus 50μg/ml HA (or no HA) for various 
time intervals (e.g. 0, 5min, 15min or 60min) at 37°C] was also used for goat anti-Nanog 
antibody-conjugated immunoprecipitation followed by rabbit anti-Stat-3-mediated 
immunoblot, respectively.
In some cases, cell lysate of HSC-3 cells [pretreated with anti-CD44 antibody or transfected 
with Nanog siRNA or Stat-3 siRNA or siRNA with scrambled sequences; or anti-miR-21 
inhibitor or miRNA-negative control or without any treatment) followed by HA (50μg/ml) 
addition (or no HA addition) for various time intervals (e.g. 0, 5min, 10min, 15min, 30min, 
60min or 24h) at 37°C] were also immunoblotted using various immuno-reagents [e.g., 
mouse anti-PDCD4 (2μg/ml) or mouse anti-c-IAP-1 or mouse anti-c-IAP-2 antibody and 
anti-XIAP (2μg/ml) or goat anti-actin (2μg/ml) (as a loading control), respectively].
Chromatin Immunoprecipitation (ChIP) Assay
To examine whether Nanog-Stat-3 complex directly interacts with the upstream promoter/
enhancer region of miR-21, chromatin immunoprecipitation (ChIP) assays was performed in 
HNSCC cells [pretreated with anti-CD44 antibody or transfected with Nanog siRNA or 
Stat-3 siRNA or siRNA with scrambled sequences] treated with HA (50μg/ml) or without 
HA using a kit (EZ ChIP) from Millipore Corp according to the manufacturer’s instructions. 
Cross-linked chromatin lysates were sonicated and diluted with ChIP sonication buffer plus 
protease inhibitors, divided and incubated with normal rabbit IgG or rabbit anti-Nanog 
antibody or rabbit anti-Stat-3 antibody or rabbit anti-phospho-Stat-3 (pY[705]) antibody at 
4°C overnight, then precipitated with protein G-agarose. Cross-linking was reversed by 
overnight 65°C incubation; DNA fragments were then extracted with PCR purification kit, 
analyzed by PCR and quantitated by real-time PCR using primer pairs specific for the 
miR-21 upstream promoter/enhancer region containing the Stat-3 binding sites: forward 
primer: 5′-CTGGGAGAAACCAAGAGCTG-3′ and reverse 
primer:AGGGGACAAGTCAGAGAGAGG-3′ on an agarose gel as described previously 
(Löffler, et al., 2007).
RNase Protection Assay Analysis of Mature miRNAs
Expression of miRNAs was qualitatively analyzed by RNase protection assay. For RNase 
protection assay, enriched small RNA isolated from HSC-3 cells [transfected with 
scrambled sequence siRNA with (or without) anti-CD44 antibody or transfected with Nanog 
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siRNA or Stat-3 siRNA or siRNA or anti-miR-21 inhibitor or miRNA-negative control in 
the presence or absence of HA for various time intervals (e.g., 0, 5min, 10min, 15min, 
30min or 2h) at 37°C] was enriched and purified using the mirVana miRNA Isolation kit 
(Ambion). RNA concentrations were verified by measuring absorbance (A260) on the 
NanoDrop Spectrophotometer ND-1000 (NanoDrop). The mirVana miRNA probe 
construction kit (Ambion) was used to synthesize the 32P-labeled miR-21 antisense probe 
and miR-191 probe loading control as described previously (Bourguignon, et al., 2009a).
Immunofluorescence Staining
HSC-3 cells (untreated or pretreated with anti-CD44 antibody) were incubated with HA 
(50μg/ml) at 37°C for various time intervals (e.g., 0, 10, 30 or 60min) or with no HA. These 
cells were then fixed with 2% paraformaldehyde. Subsequently, these cells were rendered 
permeable by ethanol treatment followed by incubating with Texas Red-conjugated anti-
Nanog antibody and fluorescein (FITC)-conjugated anti-Stat-3 antibody followed by DAPI 
staining (a marker for nucleus). To detect non-specific antibody binding, DAPI-labeled cells 
were incubated with FITC or Texas Red-conjugated normal IgG, respectively. No labeling 
was observed in control samples. These fluorescence-labeled samples were then examined 
with a confocal laser scanning microscope.
Clinical Tumor Samples
IRB approval was obtained from our institution’s Committee on Human Research. The 
clinical tissue specimens were portions of primary tumors of patients undergoing surgical 
treatment of head and neck squamous cell carcinomas (HNSCC) from multiple primary sites 
of the upper aerodigestive tract at a UCSF university-affiliated Veterans Affairs Medical 
Center from September 1, 2001 to June 30, 2006. The presence of ≥80% cancer cells in the 
procured samples was confirmed by a clinical pathologist as described previously (Wang et 
al., 2009).
Immunohistochemistry
The tissue specimens were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer for 24 
hours at 4°C and embedded in paraffin. Five μm-thick tissue sections were placed on 
positively charged glass slides (Fisher Scientific, Pittsburgh, PA, USA). 
Immunohistochemical stains were performed using the Vectastain ABC kit (Vector 
Laboratories, Burlingame, CA, USA), according to the manufacturer’s protocol. Rabbit anti-
Nanog antibody or rabbit anti-Stat-3 antibody (dilution factor from 1:100 up to 1:1000 
determined by titration) were applied to tissue sections and incubated overnight at 4°C. 
Secondary biotinylated antibody and streptavidin-HRP conjugate complex were applied for 
60 and 30 minutes, respectively. After washing in buffer, the chromogen diaminobenzidine 
was applied for 5 minutes followed by a counterstain with Mayer’s hematoxylin. Negative 
controls included substituting the primary antisera with preimmune sera from the same 
species and omitting the primary antibody, or by using an antibody of irrelevant specificity. 
In some cases, these clinical samples were also incubated with Texas Red-conjugated anti-
Nanog antibody and fluorescein (FITC)-conjugated anti-Stat-3 antibody or rabbit anti-
phospho-Stat-3 (pY[705] antibody, respectively. To detect non-specific antibody binding, 
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HNSCC tumor sections were also incubated with FITC or Texas Red-conjugated normal 
IgG, respectively. No labeling was observed in control samples. These fluorescence-labeled 
samples were then examined with a confocal laser scanning microscope.
Tumor Cell Growth and Apoptosis Assays
HSC-3 cells were transfected with either scrambled sequence siRNA or with Nanog siRNA 
(or Stat-3 siRNA) or anti-miR-21 inhibitor or miRNA-negative control or pretreated with 
anti-CD44 antibody, as above. Some cells were also treated with an IAP inhibitor, SM164 
(2nM) or vehicle control. These cells (5 × 103 cells/well) were then incubated with various 
concentrations of cisplatin (4 × 10−9M - 1.75× 10−5M) with no HA or with HA (50ug/ml). 
After 24h incubation at 37°C, MTT-based growth assays were analyzed as described 
previously (Bourguignon, 2008, 2009a, 2009b). The percentage of absorbance relative to 
untreated controls (i.e., cells treated with neither HA nor chemotherapeutic drugs) was 
plotted as a linear function of drug concentration. The 50% inhibitory concentration (IC50) 
was identified as a concentration of drug required to achieve a 50% growth inhibition 
relative to untreated controls. For apoptosis assay, FITC-conjugated Annexin V (for 
measuring apoptotic cells) using Apoptosis Detection Kit (Calbiochem, San Diego, CA) was 
used according to the manufacturer’s protocol (Bourguignon, et al., 2009b).
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Fig. 1. Analyses of Nanog and Stat-3 expression in HNSCC patient samples and HSC-3 cells
A: Detection of Nanog and Stat-3 expression in head and neck squamous cell carcinoma 
(HNSCC) primary tumors. A panel of immune-reagents including rabbit anti-Nanog 
antibody, rabbit anti-Stat-3 antibody or rabbit anti-phospho-Stat-3 (pY[705]) antibody were 
used to examine the expression of both Nanog and Stat-3 in HNSCC primary tumors using 
immuno-peroxidase staining (a and b) or co-localization of Nanog with phosphorylated 
Stat-3 (p-Stat-3) (c-e) and total stat-3 (f-h) using double immunofluorescence staining as 
described in the Materials and Methods.
B: Time course analyses of HA/CD44-induced Stat-3 tyrosine phosphorylation: Cell lysates 
were prepared from HSC-3 treated with HA (50μg/ml) for various time intervals (e.g., 0, 5, 
10, 15 and 60min) followed by anti-CD44-immunoprecipitation followed by 
immunoblotting with anti-phospho-Stat-3 [pY705] antibody or anti-CD44 antibody (as a 
loading control).
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C: Detection of Nanog and Stat-3 (or phosphorylated Stat-3) in the CD44 complex by anti-
CD44-immunoprecipitation followed by immunoblotting with anti-Nanog antibody (a) or 
anti-Stat-3 antibody (b) or anti-phospho-Stat-3 [pY705] antibody (c) or reblotting with anti-
CD44 (d) as a loading control using HSC-3 cells treated with no HA or with HA (50μg/ml) 
for 5min or pretreated with anti-CD44 antibody for 1h followed by 5min HA (50μg/ml) 
addition.
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Fig. 2. Immunocytochemical and biochemical analyses of HA/CD44-induced Nanog and Stat-3 
nuclear translocation in HSC-3 cells
A: Immunostaining of Nanog [using Texas Red-labeled anti-Nanog (red color) and Stat-3 
using FITC-labeled anti-Stat-3 (green color)]: HSC-3 cells (untreated or pretreated with anti-
CD44 antibody for 1h) were incubated with HA (50μg/ml) (or without HA) for 15min at 
37°C and fixed by 2% paraformaldehyde. Subsequently, these cells were rendered 
permeable by ethanol treatment and immuno-stained with Texas Red-labeled anti-Nanog 
(red color) or FITC-labeled anti-Stat-3 (green color) and DAPI (a nuclear marker) (c) as 
described in the Materials and Methods. B: Analyses of HA/CD44-induced Nanog and 
Stat-3 complex formation in the nuclear fraction: HSC-3 cells (untreated or pretreated with 
anti-CD44 antibody for 1h) were incubated with HA (50μg/ml) (or without HA) for 15min 
at 37°C. Nuclear fractions of these cells were then prepared by anti-Nanog-
immunoprecipitation followed by immunoblotting with anti-Stat-3 antibody (a) or anti-
phospho-Stat-3 (pY705) (b) or reblotting with anti-Nanog (c) as a loading control as 
described in the Materials and Methods [untreated cells (-HA); cells treated with HA (+HA) 
for 15min; lane 3: cells pretreated with anti-CD44 antibody for 1h plus 15min HA addition 
(anti-CD44 +HA)].
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[The ratio of Stat-3 or phosphorylated Stat-3 and Nanog (the loading control) (d) was 
determined by densitometry, and the levels were normalized to untreated (no HA treatment) 
value (designated as 1.00); the values expressed represent an average of triplicate 
determination of 3 experiments with an SD of less than 5%].
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Fig. 3. Interaction between Nanog, Stat-3 and the upstream promoter/enhancer region of miR-21 
promoter in HSC-3 cells
A: In vivo binding of Nanog and Stat-3 (or phosphorylated Stat-3) to the miR-21 upstream 
promoter/enhancer region in HSC-3 cells: ChIP assay was performed in HSC-3 cells 
following protocols described in the Materials and Methods using the Stat-3 binding site-
containing miR-21 promoter (upstream promoter/enhancer region)-specific primers by PCR. 
Identical volumes from the final precipitated materials were used for the PCR reactions 
[untreated cells (lane 1); cells treated with HA for 30min (lane 2); cells pretreated with anti-
CD44 antibody for 1h plus 30min HA addition (lane 3); cells pretreated with scrambled 
siRNA with no HA (lane 4); cells pretreated with scrambled siRNA plus 30min HA addition 
(lane 5); cells pretreated with Nanog siRNA plus 30min HA addition (lane 6); cells 
pretreated with Stat-3 siRNA plus 30min HA addition) (lane 7). (a: anti-Stat-3-mediated 
immunoprecipitated material; b: anti-phospho-Stat-3 (pY705)-mediated immunoprecipitated 
material; c: anti-Nanog-mediated immunoprecipitated material; d: IgG isotype control-
mediated precipitated material; e: total input materials). B: Verification of the specificity of 
Nanog siRNA or Stat-3 siRNA used in the study.
Cell lysates isolated from HSC-3 cells [transfected with Nanog siRNA or Stat-3 siRNA-
target or scrambled siRNA] were solubilized by 1% Nonidet P-40 (NP-40) buffer followed 
by immunoblotting with anti-Stat-3 antibody (a), anti-Nanog antibody (b) or anti-actin (a 
loading control) (c).
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Fig. 4. Detection of HA/CD44-induced miR-21 production in HSC-3 cells
Detection of miR-21 in HSC-3 cells using RNase protection assay as described in the 
Materials and methods. A: Autoradiogram of miR-21 detected in HSC-3 cells incubated 
with scrambled sequence siRNA [without HA (lane 1) or with 2h HA treatment (lane 2) or 
pretreated with anti-CD44 antibody for 1h followed by HA addition for 2h (lane 3) or 
incubated with Nanog siRNA plus 2h HA treatment (lane 4) or incubated with Stat-3 siRNA 
plus 2h HA treatment (lane 5) or incubated with miRNA-negative control [without HA (lane 
6) or with 2h HA treatment (lane 7)] or incubated with an anti-miR-21 inhibitor plus 2h HA 
treatment (lane 8). (Autoradiogram of miR-191 in each gel lane was used as a loading 
control).
Bourguignon et al. Page 21
Oncogene. Author manuscript; available in PMC 2012 July 12.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 5. Analyses of HA/CD44-mediated PDCD4 and IAP expression in HSC-3 cells
Detection of HA/CD44-induced PDCD4 and IAP (cIAP-1, cIAP-2 and XIAP) expression in 
HSC-3 cells was performed by solubilizing cells with 1% Nonidet P-40 (NP-40) buffer 
followed by immunobloting with anti-PDCD4 antibody or anti-cIAP-1 antibody or anti-
cIAP-2 antibody or anti-XIAP antibody, respectively as described in the Materials and 
Methods.
First, cell lysates were prepared from HSC-3 cells treated with scrambled sequence siRNA 
[without HA (lane 1) or with HA for 24h (lane 2)] or treated with anti-CD44 antibody for 1h 
followed by 24h HA addition (lane 3) or treated with Nanog siRNA plus HA for 24h (lane 
4) or treated with Stat-3 siRNA plus HA for 24h (lane 5) or treated with miRNA-negative 
control [without HA (lane 6) or with HA for 24h (lane 7)] or treated with anti-miR-21 
inhibitor plus HA for 24h (lane 8). These samples were then immunoblotted with anti-
PDCD4 antibody (a) or anti-cIAP-1 antibody (b) or anti-cIAP-2 antibody (c) or anti-XIAP 
antibody (d), respectively. The amount of actin detected by anti-actin-mediated immunoblot 
(e) in each gel lane was used as a loading control.
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Fig. 6. A proposed model for HA/CD44-mediated Nanog and Stat-3 signaling in the regulation of 
miRNA-21 production, oncogenesis and chemoresistence in HNSCC cells
The binding of HA to CD44 (step 1) promotes a complex formation between Nanog/Stat-3 
(also tyrosine phosphorylated Stat-3, p-Stat-3) and CD44 (step 2). Both Nanog and Stat-3 
(p-Stat-3) then translocate from the cytosol to the nucleus and interacts with the Stat-3-
binding sites located at the upstream promoter/enhancer region of miR-21 (step 4), resulting 
in miR-21 gene expression and mature miR-21 production (step 5). The resultant miR-21 
then functions to downregulate the tumor suppressor protein (PDCD4) (step 6a, indicated by 
the arrow with solid lines) and promote HNSCC activation leading to IAP (c-IAP-1, c-IAP-2 
and XIAP) expression, HNSCC cell anti-apoptosis/survival and chemoresistance (step 7a, 
indicated by the arrow with solid lines).
In direct contrast, treatment of HNSCC cells with an anti-miR-21 inhibitor induces tumor 
suppressor protein (PDCD4) upregulation (step 6b, indicated by the arrow with dash lines). 
Subsequently, these changes result in HNSCC cell inactivation including inhibition of IAP 
(c-IAP-1, c-IAP-2 and XIAP) expression (Fig. 7b, indicated by the arrow with dash lines), 
stimulation of apoptosis and enhancement of chemosensitivity in HNSCC cells. This newly-
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discovered Nanog/Stat-3 signaling pathway leading to miR-21 functioning should provide 
important drug targets for sensitizing tumor cell apoptosis and overcome chemoresistance in 
HA/CD44-activated head and neck cancer cells.
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Table 1A
Effects of various signaling perturbation agents on cisplatin-induced apoptosis and cell growth inhibition in 
HSC-3 cells.
Treatments
Apoptotic Cells (Annexin V-positive cell/total cells x 
100%)*
Cisplatin-Induced Tumor 
Cell Growth Inhibition 
IC50 (μM)**No Cisplatin + Cisplatin
Scrambled siRNA-treated cells (No HA) 13 ± 3 47 ± 7 1.00
Scrambled siRNA-treated cells (+ HA) 4 ± 1 9 ± 3 40.00
Scrambled siRNA + Anti-CD44-treated cells 
(+HA)
11 ± 2 51 ± 4 1.00
Nanog siRNA-treated cells (+ HA) 16 ± 1 86 ± 6 0.30
Stat-3 siRNA-treated cells (+ HA) 14 ± 2 71 ± 4 0.10
miRNA negative control-treated cells (No HA) 15 ± 3 55 ± 5 0.75
miRNA negative control-treated cells (+ HA) 8 ± 6 14 ± 2 30.00
Anti-miR-21 inhibitor-treated cells (+ HA) 14 ± 2 64 ± 7 0.10
*Cells were designated apoptotic when displaying Annexin V-positive staining. In each sample, at least 500 cells from five different fields were 
counted, with the percentage of cisplatin (2h treatment)-induced apoptotic cells calculated as Annexin V-positive cells/total number of cells. The 
values are presented as the means±standard deviation. All assays consisted of at least six replicates and were performed on at least 3–5 different 
experiments.
**
Tumor cell growth inhibition (IC50) is designated as “the μM concentration of chemotherapeutic drug (e.g., cisplatin-24h treatment) that causes 
50% inhibition of tumor cell growth” using MTT-based growth assay as described in the Materials and Methods. IC50 values are presented as the 
means±standard deviation. All assays consisted of at least six replicates and were performed on at least 3–5 different experiments.
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Table 1B
Effects of an IAP inhibitor (SM-164) on cisplatin-induced apoptosis and cell growth inhibition in HSC-3 cells
Treatments
Apoptotic Cells (Annexin V-positive cell/total cells x 
100%)* Cisplatin-Induced Tumor Cell 
Growth Inhibition IC50 (μM)**
No Cisplatin + Cisplatin
Vehicle control-treated cells (No HA) 13 ± 2 42 ± 4 1.0
Vehicle control-treated cells (+ HA) 6 ± 3 14 ± 4 35.00
SM-164-treated cells (no HA) 27 ± 6 87 ± 6 0.05
SM-164-trerated cells (+ HA) 12 ± 4 68 ± 9 0.10
*Cells were designated apoptotic when displaying Annexin V-positive staining. In each sample, at least 500 cells from five different fields were 
counted, with the percentage of cisplatin (2h treatment)-induced apoptotic cells calculated as Annexin V-positive cells/total number of cells. The 
values are presented as the means±standard deviation. All assays consisted of at least six replicates and were performed on at least 3–5 different 
experiments.
**
Tumor cell growth inhibition (IC50) is designated as “the μM concentration of chemotherapeutic drug (e.g., cisplatin-24h treatment) that causes 
50% inhibition of tumor cell growth” using MTT-based growth assay as described in the Materials and Methods. IC50 values are presented as the 
means±standard deviation. All assays consisted of at least six replicates and were performed on at least 3–5 different experiments.
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